Emerging therapeutic regimes for the management of mycetomas

Bibliography

• Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med Int Health 2002;7:788-92
   PubMed Web of Science ®Google Scholar
• Lupi O, Tyring SK, McGinnis MR. Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol 2005;53:931-51
   PubMed Web of Science ®Google Scholar
• Welsh O, Vera-Cabrera L, Salinas-Carmona MC. Mycetoma. Dermatol Clin 2007;25(2):195-202
   PubMed Web of Science ®Google Scholar
• Ahmed AO, Mukhtar MM, Kool-Sijmons M, et al. Development of a species-specific PCR-restriction fragment length polymorphism analysis procedure for the identification of Madurella mycetomatis. J Clin Microbiol 1999;37:3175-8
   PubMed Web of Science ®Google Scholar
• Desnos-Ollivier M, Bretagne S, Dromer F, et al. Molecular identification of black-grain mycetoma agents. J Clin Microbiol 2006;44:3517-23
   PubMed Web of Science ®Google Scholar
• Van De Sande WW, Janse DJ, Hira V, et al. Translationally controlled tumour protein from Madurella mycetomatis, a marker for tumorous mycetoma progression. J Immunol 2006;177:1997-2005
   PubMed Web of Science ®Google Scholar
• Van De Sande WW, Fahal A, Verbrugh H, Van Belkum A. Polymorphisms in genes involved in innate immunity predispose toward mycetoma susceptibility. J Immunol 2007; 179(5):3065-74
   PubMed Web of Science ®Google Scholar
• Borman AM, Linton CJ, Miles SJ, Johnson EM. Molecular identification of pathogenic fungi. J Antimicrob Chemother 2008;61(Suppl 1):7-12
   PubMed Web of Science ®Google Scholar
• Rippon J. Mycetoma. In: Rippon J, editor, Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. 3rd edition. Philadelphia, PA: WB Saunders; 1998. p. 325-52
   Google Scholar
• McGinnis MR, Padhye AA. Fungi causing eumycotic mycetoma. In: Murray PR, Baron EJ, Jorgensen JH, et al., editors, Manual of clinical microbiology. 7th edition. Washington, DC: American Society of Microbiology Press; 2003. p. 1848-56
   Google Scholar
• Mariat F, Destombes P, Segretain G. The mycetomas: clinical features, pathology, etiology and epidemiology. Contrib Microbiol Immunol 1977;4:1-39
   PubMedGoogle Scholar
• Lopez-Martinez R, Mendez-Tovar JL, Lavalle P, et al. Epidemiology of mycetoma in Mexico: study of 2,105 cases (in Spanish). Gac Med Mex 1992;128(4):477-81
   PubMedGoogle Scholar
• Castro LG, Piquero-Casals J. Clinical and mycologic findings and therapeutic outcome of 27 mycetoma patients from São Paulo, Brazil. Int J Dermatol 2008;47(2):160-3
   PubMed Web of Science ®Google Scholar
• El Hag IA, Fahal AH, Khalil EAG. Fine needle aspiration cytology of mycetoma. Acta Cytol 1996;40(3):461-4
   PubMed Web of Science ®Google Scholar
• Padhye AA, McGinnis MR. Fungi causing eumycotic mycetoma. In: Murray PR, Baron EJ, Pfaller MA, et al. editors, Manual of clinical microbiology. 7th edition. Washington, DC: American Society of Microbiology Press; 1999. p. 1318-26
   Google Scholar
• Joshi KR, Singhvi S. Serodiagnosis of mycetoma. Trans R Soc Trop Med Hyg 1988;82:334
   PubMed Web of Science ®Google Scholar
• Salinas-Carmona MC, Welsh O, Casillas SM. Enzyme-linked immunosorbent assay for serological diagnosis of Nocardia brasiliensis and clinical correlation with mycetoma infections. J Clin Microbiol 1993;31:2901-6
   PubMed Web of Science ®Google Scholar
• Salinas-Carmona MC. Anti-Nocardia brasiliensis antibodies in patients with actinomycetma and their clinical usefulness. Gac Med Mex 2001;137(1):1-8
   PubMedGoogle Scholar
• Fahal AH, El Sheikh HA, El Lider MA, et al. Ultrasonic imaging in mycetoma. Br J Surg 1997;78:765-6
   Google Scholar
• Fahal AH, Hassan MA. Mycetoma. Br J Surg 1992;79:1138-41
   PubMed Web of Science ®Google Scholar
• Fahal AH. Evidence based guidelines for mycetoma patients' management. 2000. Mycetoma Research Centre homepage. Available from: www.mycetoma.org
   Google Scholar
• Del Giudice P. Treatment of eumycetoma. J Am Acad Dermatol 1998;39:137
   PubMedGoogle Scholar
• Mahgoub ES. Medical management of mycetoma. Bull WHO 1976;54:3003-311
   Google Scholar
• Welsh O, Salinas MC, Rodriquez MA. Treatment of eumycetoma and actinomycetoma. Curr Top Med Mycol 1995;6:47-71
   PubMedGoogle Scholar
• Mahgoub ES, Gumaa SA. Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg 1984;78:376-9
   PubMed Web of Science ®Google Scholar
• Venugopal PV, Venugopal TV. Treatment of eumycetoma with ketoconazole. Aust J Dermatol 1993;34:27-9
   PubMedGoogle Scholar
• Poncio Mendes R, Negroni R, Bonifaz A, Pappagianis D. New aspects of some endemic mycoses. Med Mycol 2000;38(Suppl 1):237-41
   PubMed Web of Science ®Google Scholar
• Smith EL, Kutbi S. Improvement of eumycetoma with itraconazole. J Am Acad Dermatol 1997;34(2 Part 1):279-80
   Google Scholar
• McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol. 1998;36:2353-5
   PubMed Web of Science ®Google Scholar
• Ahmed AOA, Van De Sande WW, Van Vianen W. In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay. Antimicrob Agents Chemother 2004;48(7):2742-6
   PubMed Web of Science ®Google Scholar
• N'diaye B, Dieng MT, Perez A, et al. Clinical efficacy and safety of oral terbinafine in fungal mycetoma. Int J Dermatol 2006;45:154-7
   PubMed Web of Science ®Google Scholar
• Lacroix C, De Kerviller E, Morel P, et al. Madurella mycetomatis mycetoma treated successfully with oral voriconazole. Br J Dermatol 2005;152:1067-8
   PubMed Web of Science ®Google Scholar
• Loulergue P, Hot A, Dannaoui E, et al. Successful treatment of black-grain mycetoma with voriconazole. Am J Trop Med Hyg 2006;75(6):1106-7
   PubMed Web of Science ®Google Scholar
• Schaenman JM, Digiulio DB, Mirels LF, et al. Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol 2005;43:973-7
   PubMed Web of Science ®Google Scholar
• Porte L, Khatibi S, Hajj LE, et al. Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole. Trans R Soc Trop Med Hyg 2006;100:891-4
   PubMed Web of Science ®Google Scholar
• Mouas H, Lutsar I, Dupont B, et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 2005;40:1141-7
   PubMed Web of Science ®Google Scholar
• Negroni R, Tobon A, Bustamante B, et al. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo 2005;47:339-46
   PubMedGoogle Scholar
• Bonifaz A, Flores P, Saul A, et al. Treatment of actinomycetoma due to Nocardia spp. with amoxicillin-clavulanate. Br J Dermatol 2007;156(2):308-11
   PubMed Web of Science ®Google Scholar
• Welsh O, Sauceda E, Gonzalez J, Ocampo J. Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma. J Am Acad Dermatol 1987;17:443-8
   PubMed Web of Science ®Google Scholar
• Mahaisavariya P, Chaiprasert A, Sivayathorn A, Khemngern S. Deep fungal and higher bacterial skin infections in Thailand: clinical manifestations and treatment regimens. Int J Dermatol 1999;38:279-84
   PubMed Web of Science ®Google Scholar
• Gugnani HC, Suselan AV, Anikwe RM, et al. Actinomycetoma in Nigeria. J Trop Med Hyg 1981;84(6):259-63
   PubMed Web of Science ®Google Scholar
• Fahal AH. Mycetoma: a thorn in the flesh. Trans R Soc Trop Med Hyg 2004;98:3-11
   PubMed Web of Science ®Google Scholar
• Mahgoub ES. Treatment of actinomycetoma with sulphamethoxazole plus trimethoprim. Am J Trop Med Hyg 1972;21(3):332-5
   PubMed Web of Science ®Google Scholar
• Welsh O. Mycetoma. Current concepts in treatment. Int J Dermatol 1991;30:387-98
   PubMed Web of Science ®Google Scholar
• Dieng MT, Niang SO, Diop B, Ndiaye B. Actinomycetomas in Senegal. Study of 90 cases (in French). Bull Soc Pathol Exot Filiales 2005;98:18-20
   Google Scholar
• Smego RA, Moeller MB, Gallis HA. Trimethoprim-sulfamethoxazole therapy for Nocardia infections. Arch Intern Med 1983;143:711-8
   PubMedGoogle Scholar
• Ramam M, Bhat R, Garg T, et al. A modified two-step treatment for actinomycetoma. Indian J Dermatol Venereol Leprol 2007;73:235-9
   PubMed Web of Science ®Google Scholar
• Welsh O, Lopez R. Micetomas con diseminacion pulmonary (in Spanish). Med Cutan Ibero Lat Am 1985;13:517-23
   PubMedGoogle Scholar
• Gombert ME, Aulicino TM. Synergism of imipenem and amikacin in combination with other antibiotics against Nocardia asteroides. Antimicrob Agents Chemother 1983;24(5):810-1
   Google Scholar
• Gomez-Flores A, Welsh O, Said-Fernández S, et al. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. Antimicrob Agents Chemother 2004;48(3):832-7
   PubMed Web of Science ®Google Scholar
• Wallace RJ, Nash DR, Johnson WK, et al. β-Lactam resistance in Nocardia brasiliensis is mediated by β-lactamase and reversed in presence of clavulanic acid. J Infect Dis 1987;156:959-66
   PubMed Web of Science ®Google Scholar
• Steingrube VA, Wallace RJ, Brown BA, et al. Acquired resistance of Nocardia brasiliensis to clavulanic acid related to a change in beta-lactamase following therapy with amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991;35:524-8
   PubMed Web of Science ®Google Scholar
• Baril L, Boiron P, Manceron V, et al. Refractory craniofacial actinomycetoma due to Streptomyces somaliensis that required salvage therapy with amikacin and imipenem. Clin Infect Dis 1999;29(2):460-1
   PubMed Web of Science ®Google Scholar
• Khardori N, Shawar R, Gupta R, et al. In vitro antimicrobial susceptibilities of Nocardia species. Antimicrob Agents Chemother 1993;37(4):882-4
   PubMed Web of Science ®Google Scholar
• Kashima M, Kano R, Mikami Y, et al. A successfully treated case of mycetoma due to Nocardia veterana. Br J Dermatol 2005;152(6):1349-52
   PubMed Web of Science ®Google Scholar
• McNeil MM, Brown JM, Jarvis WR, Ajello L. Comparison of species distribution and antimicrobial susceptibility of aerobic actinomycetes from clinical specimens. Rev Infect Dis 1990;12:778-83
   PubMedGoogle Scholar
• Kageyama A, Hoshino Y, Watanabe M, et al. Clinical isolates of Nocardia brasiliensis from Japan exhibit variable susceptibility to the antibiotic imipenem. Mycopathologia 2004;158(3):275-8
   PubMed Web of Science ®Google Scholar
• Fernandez RF, Arenas R, Reyes M, Zacarias R. Micetoma dorsal por Nocardia brasiliensis. Comunicacion de un caso curado con imipenem y amikacina (in Spanish). Dermatol Rev Mex 2005;49:178-81
   Google Scholar
• Fuentes A, Arenas R, Reyes M, et al. Actinomycetoma and Nocardia sp. Report of five cases treated with imipenem or imipenem plus amikacin (in Spanish). Gac Med Mex 2006; 142:247-52
   PubMedGoogle Scholar
• Fernandez RF, Arenas R: Imipenem. An alternative treatment for actinomycetoma: an appraisal (in Spanish). Monogr Dermatol 2006;19:48-54
   Google Scholar
• Chaudhuri BN, Maiti PK, Sil J. Antibiotic sensitivity patterns of actinomycetes isolated from patients with actinomycetomas. Indian J Med Res 1997;105:162-6
   PubMed Web of Science ®Google Scholar
• Vera-Cabrera L, Gomez-Flores A, Escalante-Fuentes WG, Welsh O. In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis. Antimicrob Agents Chemother 2001;45:3629-30
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Ward SC, Crist CJ, et al. In vitro activities of linezolid against multiple Nocardia species. Antimicrob Agents Chemother 2001;45:1295-7
   PubMed Web of Science ®Google Scholar
• Moylett EH, Pacheco SE, Brown-Elliott BA, et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis 2003;36:313-8
   PubMed Web of Science ®Google Scholar
• Vera-Cabrera L, Gonzalez E, Rendon A, et al. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob Agents Chemother 2006;50(9):3170-2
   PubMed Web of Science ®Google Scholar
• Espinoza-González NA, Welsh O, De Torres NW, et al. Efficacy of DA-7218, a new oxazolidinone prodrug, in the treatment of experimental actinomycetoma produced by Nocardia brasiliensis. Molecules 2008;13(1):31-40
   PubMed Web of Science ®Google Scholar
• Daw-Garza A, Welsh O, Said-Fernández S, et al. In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis. Antimicrob Agents Chemother 2008;52(4):1549-50
   PubMed Web of Science ®Google Scholar
• Ahmed AO, Abugroun ES. Unexpected high prevalence of secondary bacterial infection in patients with mycetoma. J Clin Microbiol 1998;36:850-1
   PubMed Web of Science ®Google Scholar
• Gunduz K, Orguc S, Demireli P, et al. A case of mycetoma successfully treated with itraconazole and co-trimoxazole. Mycoses 2006;49:436-8
   PubMed Web of Science ®Google Scholar
• Fahal AH, Hassan MA, Sanhouri M. Surgical treatment of mycetoma. Sudan Med J 1994;32:98-104
   Google Scholar
• Bonifaz A, Ibarra G, Saul A, et al. Mycetoma in children: experience with 15 cases. Pediatr Infect Dis J 2007;26(1):50-2
   PubMed Web of Science ®Google Scholar
• Bonifaz A, Ibarra G, Saul A, et al. Actinomycetoma in children and adults (in Spanish). Monograf Dermatol 2006;19(1):17-23
   Google Scholar
• Stefano PC, Noriega AL, Kobrin AL, et al. Primary cutaneous nocardiosis in immunocompetent children. Eur J Dermatol 2006;16(4):406-8
   PubMed Web of Science ®Google Scholar
• Nolt D, Wadowsky RM, Green M. Lymphocutaneous Nocardia brasiliensis infection: a pediatric case cured with amoxicilin/clavulanate. Pediatr Infect Dis J 2000;19(10):1023-5
   PubMed Web of Science ®Google Scholar